XORTX Therapeutics (XRTX) Long-Term Debt Issuances (2020 - 2026)

XORTX Therapeutics' Long-Term Debt Issuances history runs 7 years deep, the most recent figure standing at $17132.0 for Q1 2026.

• Quarterly Long-Term Debt Issuances changed N/A year-over-year to $17132.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $757137.0 (changed N/A YoY) and the FY2025 annual result came in at -$738433.0, down 210.56% from the prior year.
• Long-Term Debt Issuances was $17132.0 for Q1 2026 at XORTX Therapeutics, down from $111028.0 in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $511271.0 in Q4 2024 and bottomed at $6210.0 in Q1 2023.
• A 5-year average of $178818.4 and a median of $111028.0 in 2025 frame the typical range for Long-Term Debt Issuances.
• Annual changes were most pronounced in 2022 — Long-Term Debt Issuances sank 84.59% — and 2024, when it soared 2429.74%.
• XORTX Therapeutics' Long-Term Debt Issuances stood at $180630.0 in 2022, then soared by 79.06% to $323441.0 in 2023, then jumped by 58.07% to $511271.0 in 2024, then tumbled by 78.28% to $111028.0 in 2025, then tumbled by 84.57% to $17132.0 in 2026.
• Business Quant data shows XRTX's Long-Term Debt Issuances at $17132.0 in Q1 2026, $111028.0 in Q3 2025, and $92594.0 in Q2 2025.